Skip to main content
Toggle navigation
Login
Search
Home
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Favorite
Tweet
Print
Michael J. Wagner, MD
Clinical Research Director
Dana-Farber Cancer Institute
Poster(s):
(P 235) AGNOSTIC INDICATION OF IMMUNE CHECKPOINT INHIBITORS (ICI): PATTERNS OF RESPONSE OF SARCOMAS
(P 287) A PHASE 1 STUDY OF NEOADJUVANT CABOZANTINIB IN COMBINATION WITH RADIATION THERAPY FOR SARCOMAS OF THE EXTREMITIES
(P 427) PHASE 1/2 TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF PEEL-224 IN COMBINATION WITH VINCRISTINE AND TEMOZOLOMIDE IN ADOLESCENTS AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY SARCOMAS
